---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-018907"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-10-22T23:59:59+00:00"
generated_at: "2026-05-17T02:50:26.048208+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Telomir-1 reduces DNA methylation of CASP8 and GSTP1 in aggressive prostate cancer model

## Summary
- Telomir-1 decreased DNA methylation of CASP8 (apoptosis) and GSTP1 (detoxification) genes at Day 21, vs vehicle and chemo.
- Combination of Telomir-1 and chemo showed lower methylation than chemo alone, suggesting potentiation of epigenetic effects.
- Rapamycin showed initial methylation reduction at Day 10 but rebounded by Day 21; Telomir-1 showed sustained progressive decrease.
- Data derived from mice bearing human aggressive prostate tumors; preclinical, not yet in humans.

## SEC filing metadata
- accession: 0001493152-25-018907
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-10-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315225018907/0001493152-25-018907-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315225018907/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-018907
- JSON: https://secwatch.observer/filing/0001493152-25-018907.json
- Plain text: https://secwatch.observer/filing/0001493152-25-018907.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.